Professor Patrick Chinnery, an expert in diseases that affect mitochondria – the ‘batteries’ that power our cells – has been appointed as Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge. He will take up his appointment on 1 October.
The American Academy of Neurology (AAN) and the National Multiple Sclerosis Society are awarding the 2015 John Dystel Prize for MS Research to Alastair Compston, MBBS, PhD, Professor of Neurology at the University of Cambridge.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Brings to 110 known risk factors and provides important insight into disease mechanism.
Approval concludes nearly 40-year epic journey from fundamental research to discovery of an effective treatment for active relapsing multiple sclerosis
Alemtuzumab, a drug previously used to treat a type of leukaemia, shown to help people with early multiple sclerosis who relapsed on previous drugs as well as patients who had not yet been treated.
New treatment for multiple sclerosis: Cambridge University translates research at the bench into a drug at the bedside14 Nov 2011
Phase III clinical trials for new MS drug very positive.